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Neurobiology of Disease

A Murine Niemann-Pick C1 I1061T Knock-In Model
Recapitulates the Pathological Features of the Most
Prevalent Human Disease Allele
Maria Praggastis,1 Brett Tortelli,1 Jessie Zhang,1 Hideji Fujiwara,1 Rohini Sidhu,1 Anita Chacko,1 Zhouji Chen,1
X Chan Chung,2 Andrew P. Lieberman,2 Jakub Sikora,3 Cristin Davidson,3 Steven U. Walkley,3 Nina H. Pipalia,4
Frederick R. Maxfield,4 Jean E. Schaffer,1 and Daniel S. Ory1
1Diabetic Cardiovascular Disease Center and Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, 2Department
of Pathology, University of Michigan, Ann Arbor, Michigan 48109, 3Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy Intellectual and
Developmental Disabilities Research Center, Albert Einstein College of Medicine, Bronx, New York 10461, and 4Department of Biochemistry, Weill Cornell
Medical College, New York, New York 10065

Niemann-Pick Type C1 (NPC1) disease is a rare neurovisceral, cholesterol–sphingolipid lysosomal storage disorder characterized by
ataxia, motor impairment, progressive intellectual decline, and dementia. The most prevalent mutation, NPC1 I1061T, encodes a misfolded
protein with a reduced half-life caused by ER-associated degradation. Therapies directed at stabilization of the mutant NPC1 protein
reduce cholesterol storage in fibroblasts but have not been tested in vivo because of lack of a suitable animal model. Whereas the
prominent features of human NPC1 disease are replicated in the null Npc1 ⫺/⫺ mouse, this model is not amenable to examining proteostatic therapies. The objective of the present study was to develop an NPC1 I1061T knock-in mouse in which to test proteostatic therapies.
Compared with the Npc1 ⫺/⫺ mouse, this Npc1tm(I1061T)Dso model displays a less severe, delayed form of NPC1 disease with respect to
weight loss, decreased motor coordination, Purkinje cell death, lipid storage, and premature death. The murine NPC1 I1061T protein has a
reduced half-life in vivo, consistent with protein misfolding and rapid ER-associated degradation, and can be stabilized by histone
deacetylase inhibition. This novel mouse model faithfully recapitulates human NPC1 disease and provides a powerful tool for preclinical
evaluation of therapies targeting NPC1 protein variants with compromised stability.
Key words: cholesterol; lysosomal storage; neurodegeneration; Niemann-Pick C; NPC1; protein misfolding

Introduction
Niemann-Pick type C (NPC) disease is a fatal neurodegenerative
disease caused by a defect in egress of cholesterol and sphingolipids out of lysosomes, which results in a broad array of neurovisceral pathological changes including Purkinje cell death in the
cerebellum. Ninety-five percent of NPC disease results from mutations in the NPC1 gene, whereas the remaining 5% is attributed
Received Oct. 8, 2014; revised March 2, 2015; accepted April 1, 2015.
Author contributions: M.P., J.E.S., and D.S.O. designed research; M.P., B.T., J.Z., H.F., R.S., A.C., Z.C., C.C., J.S., C.D.,
and N.H.P. performed research; A.P.L. and D.S.O. contributed unpublished reagents/analytic tools; M.P., B.T., J.Z.,
H.F., R.S., J.S., C.D., S.U.W., N.H.P., F.R.M., J.E.S., and D.S.O. analyzed data; M.P., J.S., C.D., S.U.W., F.R.M., J.E.S., and
D.S.O. wrote the paper.
This work was supported by grants from the Hide & Seek Foundation (D.S.O.), Dana’s Angels Research Trust
(D.S.O., C.D., and S.U.W.), and the Ara Parseghian Medical Research Foundation (F.R.M.) and by NIH Grants R01
NS081985 (D.S.O. and J.E.S.), R37 DK27083 (F.R.M.), R01 NS063967 (A.P.L.), R01 NS053677 (S.U.W.), R01 HD045561
(S.U.W.), and P30 HD071593 (S.U.W.), and F05 NS074790 (J.S.). This work was performed in the Metabolomics
Facility at Washington University (NIH Grant P30 DK020579) and was supported in part by the Hope Center Transgenic Vectors Core at Washington University School of Medicine. We are grateful to Renate Lewis for assistance with
generation of the knock-in mouse line. The LAMP1 antibody 1D4B was obtained from the Developmental Studies
Hybridoma Bank, created by the NICHD of the NIH, and maintained at The University of Iowa.
The authors declare no competing financial interests.
Correspondence should be addressed to Dr. Daniel S. Ory, Diabetic Cardiovascular Disease Center, Washington
University School of Medicine, Box 8086, 660 S. Euclid Avenue, St. Louis, MO 63110. E-mail: dory@wustl.edu.
DOI:10.1523/JNEUROSCI.4173-14.2015
Copyright © 2015 the authors 0270-6474/15/358091-16$15.00/0

to defects in NPC2 (Millat et al., 1999; Ory, 2000; Walkley and
Suzuki, 2004). NPC patients typically present in early childhood
with progressive impairment of motor and intellectual function
and usually die within the first two decades of life (Vanier, 2010).
There are currently no Food and Drug Administration-approved
therapies for this disorder.
The NPC1 gene encodes a polytopic, highly glycosylated
transmembrane protein that localizes to the limiting membrane
of the late endosome/lysosome (Carstea et al., 1997; Davies and
Ioannou, 2000). NPC1 protein binds unesterified cholesterol
within the lysosome, interacting with NPC2 and facilitating cholesterol egress (Millard et al., 2000; Infante et al., 2008; Kwon et
al., 2009). Cells harboring mutations in NPC1 sequester unesterified cholesterol in lysosomes and exhibit impairment of mobilization and re-esterification of LDL cholesterol (Neufeld et al.,
1999; Millard et al., 2000; Wojtanik and Liscum, 2003).
The most common NPC1 mutation, I1061T (NPC1 I1061T),
represents 15–20% of all human disease alleles (Millat et al., 1999;
Davies and Ioannou, 2000; Park et al., 2003). This mutation results in misfolded NPC1 protein, which is targeted for ERassociated degradation (Gelsthorpe et al., 2008). Overexpression
of NPC1 I1061T protein results in lysosomal localization of mutant
protein and complementation of the mutant phenotype, likely
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caused by a small proportion of NPC1 I1061T
protein that assumes proper conformation
and escapes ER quality control checkpoints
(Gelsthorpe et al., 2008). Recently, histone
deacetylase (HDAC) inhibitors have been
shown to increase synthesis of NPC1 I1061T
protein and cholesterol egress from lysosomes (Kim et al., 2007; Munkacsi et al.,
2011; Pipalia et al., 2011). These findings
raise the possibility that small moleculebased proteostatic therapies might stabilize
mutant NPC1 proteins and have the potential to provide clinical benefit.
Development of proteostatic therapies
for NPC1 disease requires testing candidate
therapies in a suitable disease model. Many
of the prominent neuropathological features of human NPC disease are modeled in
the BALB/c Npc1nih (Npc1 ⫺/⫺) mouse, but
this model does not synthesize NPC1 protein and, therefore, is not amenable to
proteostatic therapies (Pentchev et al.,
1980; Morris et al., 1982; Shio et al., 1982;
Higashi et al., 1993; Loftus et al., 1997). An
npc1pf/pf knock-in mouse that ablates cholesterol binding in the NPC1 N-terminal
domain was recently generated, but the
P202A/F203A mutations result in complete loss of NPC1 function and do not
destabilize the mutant protein (Xie et
al., 2011). A second naturally occurring
mouse model, Npc1nmf164, expresses a
D1005G amino acid substitution in the
NPC1 protein; however, the D1005 residue is not conserved in human protein,
and there is no evidence that the mutation
affects protein folding or stability (Maue
et al., 2012). To address the need for an
animal model in which to test proteostatic
therapies for NPC1 disease, we generated
an Npc1tm(I1061T)Dso knock-in mouse
model (referred to as Npc1I1061T). This
novel model faithfully recapitulates disease caused by the human NPC1 I1061T
mutation and may prove useful for preclinical evaluation of proteostatic therapies for NPC1 disease.

Materials and Methods
Generation of Npc1tm(I1061T)Dso knock-in mice.
The murine Npc1 genomic locus was inserted
into a mouse 129 bacterial artificial chromosome (BAC) construct (BAC identification
number bMQ-398C12). The I1061T mutation,
I1061T
mouse model. A, Diagram of the knock-in targeting vector, the WT NPC1 allele, and the
ATA to ACA at amino acid 1061 in exon 21, Figure 1. Knock-in strategy for the Npc1
resulting
recombined
allele.
B,
Restriction
digest
of genomic DNA, followed by Southern blotting in ES cells. Genomic DNA from WT and
was introduced via galactokinase (galK)-based
⫹/I1061T
mice was digested with NdeI and HindIII to produce a 6.1 kb band from the WT allele and a 7.6 kb band from the knock-in. C,
recombineering as described previously Npc1
Electropherogram
of NPC1 cDNA sequence data, showing the ATA-to-ACA mutation at the 1061 amino acid position.
(Warming et al., 2005). A silent mutation was
also introduced at alanine 1058 (GCT to GCC)
as positive selection in embryonic stem (ES) cells. Conditional deletion of
to engineer an MspI restriction site for genotyping. A loxP site was inexons 14 –20 introduces a frameshift and multiple premature stop
serted via recombineering (Lee et al., 2001), within a nonconserved recodons, providing the option of conditional Npc1 knockout for future
gion ⬃220 bp upstream of exon 12, eliminating a wild-type (WT) NdeI
experiments. The targeting vector was generated from the engineered
site. A loxP-frt-pGK-neomycin-frt expression cassette was inserted
BAC using gap repair, inserted into a plasmid vector containing a diphwithin a nonconserved region ⬃800 bp downstream of exon 20, serving
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theria toxin cassette for negative selection in 129 ES cells (Lee et al., 2001),
and linearized for ES cell electroporation with AscI. PCR analysis was
performed using an external primer 3⬘ of the short arm and an internal
primer within the neomycin cassette. Southern blot analysis of NdeI or
NdeI/HindIII digestion products confirmed homologous recombination in the ES cells. Cells were injected into C57BL/6 blastocysts and
implanted in C57BL/6 mothers. Resulting chimeras were then bred with
FLPeR C57BL/6 mice (catalog #003946; The Jackson Laboratory) to excise the neo cassette. Excision was confirmed via PCR and HindIII digestion. These mice were then backcrossed into The Jackson Laboratory
C57BL/6 background for five generations. Mice were kept in a controlled
animal facility and given standard chow and water ad libitum. Weaning
occurred between 3 and 4 weeks. Experimental procedures were approved by the Washington University and University of Michigan Animal Studies Committees and were conducted in accordance with the
USDA Animal Welfare Act and the Public Health Service Policy for the
Humane Care and Use of Laboratory Animals.
Genotyping. Npc1tm(I1061T)Dso (referred to as Npc1I1061T) knock-in
mice were identified via a PCR-based genotyping method with the following primers: forward, 5⬘-tgatctgcacacttggaaccgag-3⬘; and reverse, 5⬘cactgccttgagcagcatctcag-3⬘. The WT Npc1 allele produced a 200 bp
fragment, whereas the knock-in allele produced a 234 bp fragment.
MspI restriction digest also confirmed the presence of the I1061T
point mutation.
Functional evaluation of mice. For animal survival and behavioral studies, the groups were balanced between males and females (Npc1 ⫺/⫺
mouse studies, four males/four females; Npc1I1061T mouse studies, six
males/six females), and the general clinical condition of the mice was
monitored daily. Mice were weighed weekly beginning at 4 weeks of age
until they died. Death was defined as either being found dead in the cage
or by the inability to eat or drink on their own, necessitating euthanasia.
Cerebellar function was evaluated weekly by measuring retention
time on a rotating drum at 15 rpm (Langmade et al., 2006). For each
run, cumulative retention time on the drum was determined for three
consecutive attempts (a maximum of 180 s per attempt). Mice were
tested in the morning and in the afternoon, and the rotarod score was
determined as the highest cumulative retention time for an individual
session.
Real-time quantitative RT-PCR. Mice were killed, and liver and cerebellum were flash-frozen in liquid nitrogen and stored at ⫺80°C. RNA
was harvested by homogenization in Trizol reagent (Invitrogen) as per
the manufacturer’s protocol. cDNA libraries were made via the Superscript III First Strand Synthesis System (Invitrogen) with provided oligo
dT primers. Real-time quantitative RT-PCR (RT-qPCR) analysis was
performed with reported primer sequences (Li et al., 2005; Liu et al.,
2010). Relative quantification of gene expression was performed using
the comparative threshold (CT) method as described previously (Millard
et al., 2005). Fold changes in the mRNA expression level were calculated
following normalization to 36B4, a ribosomal mRNA.
Protein preparation and Western blot analysis. Protein was harvested
from flash-frozen liver and brain tissues as described previously (Newberry et al., 2003). Cultured cells were harvested in RIPA buffer (10 mM
Tris-Cl, pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1%
sodium deoxycholate, 0.1% SDS, 140 mM NaCl) with Complete Protease
Inhibitor Mixture (Roche) and 1 mM phenylmethylsulfonyl fluoride and
incubated on ice for 10 min. Postnuclear supernatant was obtained by
centrifuging for 10 min at 12,000 ⫻ g at 4°C. Protein concentration was
quantified using the BCA Protein Assay kit (Pierce). Nonboiled protein
samples were resolved by 7.5% SDS-PAGE under reducing conditions.
Proteins were transferred onto polyvinylidene difluoride (0.45 mm; Millipore) using a semidry electroblotter (Owl Scientific). Western blot
analysis was performed using an affinity-purified rabbit anti-human
NPC1 antibody at a dilution of 1:2500 (Millard et al., 2000) and rabbit
anti-human HSP90 (Enzo/Stressgen) at a dilution of 1:5000. Detection
was performed by chemiluminescence using a peroxidase-conjugated
donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories) at
1:5000.
Endoglycosidase treatments. Liver and brain tissues were isolated and
protein was harvested as described previously (Newberry et al., 2003).
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Figure 2. Natural history of Npc1I1061T mice. A, Survival of Npc1I1061 T mice in days is compared
with the NIH Npc1 ⫺/⫺ model. Npc1 ⫺/⫺, n ⫽ 8; Npc1I1061T, n ⫽ 12. B, Weights of WT, heterozygous (Npc1⫹/I1061T), and homozygous (Npc1I1061T) mice, recorded weekly beginning at week 4. C,
Rotarod testing was used to evaluate motor function on a constant 15 rpm rotating drum. Values
reportedarethesumofthetimeontherotarodfor3consecutiveattempts.*p⬍0.05;**p⬍0.001.
Protein samples were incubated with endoglycosidase H (New England
Biolabs) or PNGaseF (New England Biolabs) for 7 h at 37°C in 5 mM
sodium phosphate with 1% NP-40.
Hepatocyte isolation and cycloheximide treatment. Mouse hepatocytes
were isolated from postnatal day 35 (P35) mice and cultured as described
previously (Chen et al., 2000). NPC1 I1061T homozygous fibroblasts
59413 were obtained from Dr. John O’Brien (Mayo Clinic, Rochester,
MN) and cultured as reported previously (Gelsthorpe et al., 2008). At
24 h after plating, cells were treated with 30 g/ml cycloheximide (CHX;
Sigma) in growth medium for the indicated time periods, lysed, and
subjected to Western blot analysis as described above.
Immunohistochemistry of murine tissues. Mouse tissues were collected
at indicated time points. Mice were perfused with 0.9% saline solution,
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Figure 3. Cerebellar/Purkinje cell neuropathology of Npc1I1061mice. A, Temporal progress of patterned Purkinje cell loss (brown, calbindin D; Nissl nuclear counterstain). B, Purkinje cell density evaluated in
cerebellarzones[schematicallycorrespondingto(60)].C,RT-qPCRquantificationofcalbindinDmRNAinthebrainsofWTandNpc1I1061T miceagesP28,P63,andP105(n⫽4pergroup).D,Exampleofregressive
changes in a lobule V Purkinje cell (green), reduction and dystrophy of a dendritic tree, and formation of axonal spheroids (arrows), likely affecting both the main axon and axonal collateral. Extensive microglial
pathology(purple,CD68)isobservedinmolecular,Purkinjecell,andgranularcelllayers.TheimageisaMIPofa16.2-m-thickZstack.E,StorageofcholesterolandGM2gangliosideisshowninlobuleXPurkinje
cells.F,UltrastructuralappearanceofpolymembranouscytoplasmicstoragebodiesinalobuleXPurkinjecell(cytoplasmicmembraneoutlined)ofanNpc1I1061T mousecomparedwithNpc1 ⫺/⫺ mice(equivalent
magnification of lobule X Purkinje cell cytoplasm). ML, Molecular layer; PCL, Purkinje cell layer; GCL, granule cell layer. **p ⬍ 0.001. Scale bars: A, 1 mm; D, 50 m; E, F, 5 m.
and tissue blocks were immediately drop-fixed in 4% paraformaldehyde
overnight at 4°C. Tissues were then rinsed and stored in 0.1 M phosphate
buffer at 4°C. Tissues were sectioned (35 m) and stained as described
previously (McGlynn et al., 2004; Davidson et al., 2009). Primary antibodies ␣-GM2 ganglioside (mouse, in house) and ␣-calbindin (mouse,
Sigma) were used at 1:200 and 1:3000, respectively. Biotinylated
␣-mouse IgM and ␣-mouse IgG secondary antibodies (both from Vector
Laboratories) were diluted 1:200. Sections were evaluated, and wide-field
images were acquired on a Zeiss AxioSkop2 Plus microscope with an
AxioCam MRc CCD (AxioVision 4.4 software) using 2.5⫻ (NA 0.075) or
10⫻ (NA 0.3) objectives or on an Olympus AX70 microscope with a
MagnaFire CCD (MagnaFire version 2.1 software) using a 10⫻ (NA 0.3)
objective. Images were processed, and figures were prepared in ImageJ
(version 1.48; NIH) and Adobe Photoshop (version CS6). Images were
corrected for nonspecific background and, if necessary, stretched to fit
the full dynamic eight-bit range.
Immunofluorescence staining of murine tissues. Mouse tissues were
harvested and sectioned as described above. Primary antibodies were
used at the following dilutions: ␣-GM2 ganglioside (mouse, in
house), 1:25; ␣-calbindin (mouse, Sigma), 1:3000; ␣-calbindin (rab-

bit, Millipore), 1:800; ␣-NeuN (mouse, Millipore Bioscience Research
Reagents), 1:1000; ␣-CD68 (rat, AbD Serotec), 1:1000; ␣-GFAP (mouse,
Sigma), 1:3000. Goat secondary antibodies (1:250, all from Invitrogen)
targeting the following species/isotypes and conjugated to Alexa Fluor
fluorophores (AF) were ␣-mouse IgM AF546, ␣-rat IgG AF488, ␣-mouse
IgG AF546, ␣-mouse IgG AF488, and ␣-rabbit IgG AF488. To avoid
cross-reactivity with the primary ␣-GM2 ganglioside antibody, goat
␣-mouse IgG AF488 (1:450; Jackson ImmunoResearch Laboratories)
was used. Filipin complex from Streptomyces filipinensis (Sigma) was
dissolved in DMSO (Sigma) and used at a final concentration of 0.05
mg/ml. Confocal images were acquired on a Zeiss 510 Duo V2 laserscanning microscope using 20⫻ (NA 0.80) or 63⫻ oil (NA 1.4) objectives and 351, 488, and 543 nm excitation lasers. Image acquisition
conditions (laser intensities, pinhole size, dichroic mirrors, bandpass filters, photomultiplier gains) were kept constant for particular combinations
of dyes. Emission wavelength filtering was set to minimize cross talk, and
excitation and emission collection was performed sequentially for individual
fluorophores. Selected Z stacks are presented as single-plane maximumintensity projections (MIPs).
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Figure 4. Hepatocyte and macrophage pathology in liver of Npc1I1061T mice. A, Liver macrophages (green, CD68⫹) increase in number and exhibit a progressive foamy transformation in
Npc1I1061T mice. B, Cholesterol accumulation (as visualized by filipin labeling) in both liver macrophages and hepatocytes (arrows). C, Ultrastructural pathology in liver macrophages and hepatocytes
at P63. Detailed views of polymembranous storage bodies are shown in the insets outlined by the dashed lines. Asterisks indicate nuclei; black arrows indicate biliary canaliculi, and the white arrow
indicates macrophage. Scale bars: A, 100 m; B, 10 m; C, 2 m.
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Figure 5. Hallmarks of cerebral neuropathology of Npc1I1061T mice. A, Filipin labeling of cholesterol accumulation (top row) and GM2 ganglioside staining (bottom row, brown; Nissl nuclear counterstain) within the
primarysomatosensoryneocortex.B,ImmunofluorescencestainingofneocorticalneuronsfromP63Npc1I1061T (left)andNpc1 ⫺/⫺ (right)cholesterolandGM2gangliosidestorageintheneuronalcellbodies(NeuN⫹),aswell
aswithindistendedinitialaxonalsegments(meganeurites,whitearrows).C,Microglial(CD68⫹)andastrocytic(GFAP⫹)labelinginNpc1I1061T micecomparedwithNpc1 ⫺/⫺ miceinasegmentofdeepsomatosensorycortex
(layerVI),subcorticalwhitematter,andtheadjoiningCA1segment.ImagesareMIPsof4.8-m-thickZstacks.WM,Whitematter;ctx,cortex;CA1,CA1regionofhippocampus.Scalebars:A,100 m;B,5 m;C,50 m.

Electron microscopy of murine tissues. Liver and cerebellum were processed for electron microscopy as described previously (Davidson et al.,
2009). Lobules corresponding to anterior and nodular zones were manually
dissected from 250-m-thick sagittal sections from cerebellar vermis.

Purkinje cell density counts. Densities of Purkinje cells were assessed in
individual cerebellar lobes (I–X) from three 35-m-thick midline sagittal cerebellar sections labeled with ␣-calbindin mouse Ab. Lengths of
Purkinje cell layers in individual lobules and Purkinje cells were manually
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Figure 6. In vivo characterization of NPC1 protein in Npc1I1061T tissues. A, Western blot analysis of WT (50 g protein) and Npc1I1061T (200 g protein) tissue homogenate from P28 mice. B,
Quantification of Western blot analysis in A. C, RT-qPCR analysis of NPC1 mRNA from P28 WT and Npc1I1061T tissue. D, Western blot analysis of hepatocytes isolated from P35 mice, treated with 30
g/ml CHX over an 8 h time course. E, Western blot analysis of WT and NPC1 I1061T homozygous human skin fibroblasts, treated with 30 g/ml CHX over an 8 h time course. F, Western blot analysis
of WT (200 g) and Npc1I1061T (400 g of liver, 500 g of brain) tissue homogenate treated with endoglycosidase H (EndoH) and PNGase F. Filled arrowheads indicate glycosidase-resistant species,
and open arrowheads indicate glycosidase-sensitive species. *p ⬍ 0.05.
traced/counted using an Olympus BX51 microscope equipped with 4⫻
(NA 0.13), 10⫻ (NA 0.30), and 20⫻ (NA 0.50) objectives and Stereo
Investigator software (MBF Biosciences). Densities are shown as the
number of Purkinje cells/1 mm of Purkinje cells layer length. Statistical
comparisons were calculated for average density values in cerebellar lobules, grouped based on sagittally projected transverse cerebellar zones as
described previously (Sillitoe and Joyner, 2007).
Isolation of murine embryonic fibroblasts. Mouse embryos were isolated
at day 13.5 and placed in PBS. The head and entrails were removed, and
the embryo was minced into small chunks. Chunks were transferred to a
50 ml conical, and 1 ml of trypsin (0.25% in EDTA) was added, pipetted
to initiate disaggregation. Another 0.5 ml of trypsin was added, and the
tissue was digested 15 min at room temperature with occasional vortexing. The reaction was then neutralized with medium (10% heatinactivated fetal serum, 1% nonessential amino acids, 150 M
1-thioglycerol in DMEM), and supernatant was taken as a sample. Samples were centrifuged at 1000 rpm for 10 min to pellet cells. Isolated cells
were then plated into flasks, ⬃1.25 embryos per T150.
Cell culture immunofluorescence. Murine embryonic fibroblasts
(MEFs) were plated on 12 mm circular coverslips in medium in 24-well
plates at 5 ⫻ 10 4 cells per well. Twenty-four hours after plating, cells were
fixed in 4% paraformaldehyde for 20 min and permeabilized with 0.2%
Tween 20 with 10% normal goat serum in PBS for 30 min. Cells were
stained with ␣-NPC1 antibody (rabbit, 1:250, in house), ␣-LAMP1 (rat,
1:500, University of Iowa Hybridoma Bank), and filipin (0.05 mg/ml,
Sigma) for 1 h. Cells were then incubated with rabbit Alexa Fluor 594 and
rat Alexa Fluor 488 for 1 h and mounted with Slowfade (Invitrogen).
Images were captured with the 63⫻ objective on a laser-scanning confocal microscope (LSM 700 URGB two-channel system; Carl Zeiss) with

405, 488, 555, and 635 nm solid-state lasers coupled to an Axio Imager
M2 microscope with a motorized stage and Zen software. Images were
captured with channel pinholes adjusted to 1 Airy unit.
Metabolomics. Sample preparation, instrumentation, and quantification of lipids were performed by tandem mass spectrometry as described
previously (Fan et al., 2013). For Npc1I1061T heat maps, data were normalized to the average of the P28 WT values for each lipid, and Z scores
for each lipid were generated as reported previously (Fan et al., 2013).
Heat maps for the strain comparison (see Fig. 10) were generated by
normalizing data to C57BL/6 WT and then calculating Z scores.
Treatment of Npc1 fibroblasts with suberanilohydroxamic acid. WT and
Npc1I1061T MEFs were plated in 10 cm tissue culture plates in growth medium supplemented with 10% FBS. After a 24 h incubation, the cells were
treated with 10 M suberanilohydroxamic acid (SAHA) or DMSO (vehicle
control) for 72 h in growth medium supplemented with 5.5% FBS and harvested for Western blot analysis as described previously (Pipalia et al., 2011).
Statistics. Statistical significance was calculated via the two-tailed t test
using the Holm–Sidak method, with p ⬍ 0.05 considered to be significant. In addition to the t test, a Bonferroni’s post-test correction for
multiple comparison errors was applied to all metabolomic data to determine significance between genotypes.

Results
Npc1 I1061T knock-in mice have decreased lifespan, reduced
body weight, and impaired motor function
To generate the targeting vector to introduce the I1061T point
mutation into the murine Npc1 locus, we used a BAC construct
and galK-based recombineering as described (Fig. 1A). Recom-
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bination events were confirmed in ES cells
by restriction digest and Southern blotting (Fig. 1B), and the T3179C mutation
resulting in the I1061T substitution was
confirmed by sequencing of the mRNA
(Fig. 1C). ES cells harboring the mutant
allele were then injected into pregnant
C57BL/6 females, and chimeras were bred
with FLPeR C57BL/6 mice to excise the
neomycin cassette. Analyses were performed on offspring backcrossed a minimum of five generations into the C57BL/6
background. When compared with the
Npc1 ⫺/⫺ model, Npc1I1061T mice live 59%
longer, with an average lifespan of 125 d,
consistent with expression of a partially
functional NPC1 protein (Fig. 2A). Like
Npc1 ⫺/⫺ mice, Npc1I1061T mice have significantly lower body weight compared
with their WT littermates, and growth
curves begin to diverge at 10 weeks, revealing progressive weight loss during
later stages of disease (Fig. 2B). At approximately 8 weeks of age, there is onset of a
visible resting tremor in Npc1I1061T mice,
and by 12 weeks, the mice are no longer
able to maintain balance on a rotating rod,
a test of motor coordination (Fig. 2C).
Npc1 I1061T mice exhibit neurological
and hepatopathological hallmarks of
NPC disease
The progressive loss of motor coordination in NPC1 disease is a well established
consequence of the stereotypical Purkinje
localization of Npc1I1061T protein. A, NPC1 (red) and free cholesterol (filipin; blue) immunofluorescence
cell loss in the cerebellum (Higashi et al., Figure 7. Subcellular I1061T
staining of WT and Npc1
MEFs. Exposure time for both channels is equivalent across cell types. B, NPC1 (red) and LAMP1
1993). To determine whether the neuro- (green) immunofluorescence staining of WT and Npc1I1061T MEFs. Laser power for Npc1I1061T is increased to balance channel
logical phenotype we observed in the brightness.
Npc1I1061T mice was associated with Purkinje cell degeneration, we performed caldination in the knock-in compared with the knock-out model
bindin D immunohistochemistry to visualize these neurons in
(Langmade et al., 2006).
parasagittal cerebellar sections from P28, P63, and P105 mice. In
We then investigated whether Purkinje cells from Npc1I1061T
contrast to WT littermates, cerebella from Npc1I1061T mice
mice displayed the well characterized subcellular abnormalities
showed progressive, age-dependent loss of calbindin D staining,
of NPC1 disease (Higashi et al., 1993). Immunofluorescence
predominantly in the anterior lobules, indicating loss of Purkinje
staining of cerebellar sections revealed subcellular storage of chocells (Fig. 3 A, B). The progressive Purkinje cell degeneration was
lesterol and ganglioside GM2 in Purkinje neurons from P63
also reflected in the age-dependent reduction in calbindin D
Npc1I1061T mice, similar to the pattern observed in the Npc1 ⫺/⫺
mRNA expression (Fig. 3C). In the cerebella of P63 and P105
model (Fig. 3E). We also observed subcellular ultrastructural pamice, there was a significant loss of Purkinje cells in anterior (P63,
thology in these animals, with the presence of polymembranous
58% reduction, p ⬍ 0.01; P105, 91% reduction, p ⬍ 0.001), censtorage bodies in Purkinje cells from P63 Npc1I1061T mice (Fig. 3F;
tral (P105, 80% reduction, p ⬍ 0.001), posterior (P105, 65%
Higashi et al., 1993). In addition, Npc1I1061T mice exhibited choreduction, p ⬍ 0.001), and nodular (P105, 41% reduction, p ⬍
lesterol storage in CD68-positive macrophages (Fig. 4A) and in
0.001) zones but no appreciable Purkinje cell loss in lobule X,
hepatocytes (Fig. 4B), cell types critically associated with the prowhich is generally preserved even in end-stage disease (Fig. 3B;
gression of the liver disease (Lopez et al., 2012). Electron microsLangmade et al., 2006; Davidson et al., 2009). Loss of Purkinje cell
copy similarly revealed the presence of polymembranous storage
bodies was accompanied by axonal spheroid formation, dystrobodies in both macrophages and hepatocytes (Fig. 4C). Although
phic dendritic abnormalities, and microglial and astrocytic
delayed when compared with Npc1 ⫺/⫺, the macrophage patholchanges in affected cerebellar areas (Fig. 3D). Although the disogy was particularly progressive in this novel model.
tribution of Purkinje cell loss in the Npc1I1061T mice was similar to
We also examined whether cerebral tissues from Npc1I1061T
⫺/⫺
that observed in the Npc1
model, the degree of Purkinje cell
mice exhibited the lipid storage phenotype that is the biochemical
loss at P63 was less severe than in similarly aged Npc1 ⫺/⫺ mice,
hallmark of NPC disease (Walkley and Suzuki, 2004). In neocorfindings consistent with delayed onset of impaired motor coortex, cholesterol and ganglioside storage was evident in all layers
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Figure 8. Gene expression of Npc1I1061T brain and liver tissue. A, ApoE and GFAP mRNA expression in brain. B, Expression of markers of cytokine activation (TNF␣, MIP1␣) and glial activation
(CD68, CD11c) in brain. C, Expression of markers of cytokine activation (TNF␣, MIP1␣) and macrophage activation (CD68, CD11c) in liver. Values are normalized to 36B4, and fold change is calculated
relative to WT P28 values. *p ⬍ 0.5; **p ⬍ 0.001, Npc1I1061T versus WT.

and was most abundant in layers V and VI (Fig. 5A). A substantial
portion of the metabolites localized to neuronal cell bodies; however, we also identified abnormal accumulation in meganeurites,
a feature previously described in NPC disease (Fig. 5B). To determine whether the microglia were activated in the Npc1I1061T mice,
neocortical sections were stained with CD68 and GFAP, markers
that monitor macrophage infiltration in Npc1 ⫺/⫺ brain (Langmade et al., 2006; Lopez et al., 2012). Immunofluorescence staining of neocortical sections also revealed an age-dependent
increase in microglial activity and astrocytic reactive changes in
Npc1I1061T tissue, as seen by increased CD68 and GFAP signals
(Fig. 5C). The progression and spatial pattern of microglial activation, while delayed, is similar to that reported in the Npc1 ⫺/⫺
mouse (Pressey et al., 2012).
The murine NPC1 I1061T protein is unstable and retained in
the ER
In human NPC1 mutant fibroblasts, the NPC1 I1061T protein is
misfolded and targeted for proteasomal degradation. As a result,
the half-life of the mutant NPC1 protein is decreased, and the
small amount of protein that is present is predominantly localized to the ER (Gelsthorpe et al., 2008). We hypothesized that the
murine NPC1 I1061T protein shares the same defect. To determine
whether tissues from Npc1I1061T mice have decreased NPC1 protein accumulation, we performed Western blotting of liver and
brain homogenate. Npc1I1061T mice showed dramatically decreased levels of NPC1 protein in both tissues compared with
WT, which was disproportionate to the slight decrease in NPC1
mRNA expression (Fig. 6A–C). This finding is consistent with
our previous observation in human NPC1I1061T fibroblasts, in which
there was no correlation between NPC1I1061T transcript abundance
and mutant protein levels, indicating that NPC1 protein levels are

principally regulated by translational or post-translational mechanisms rather than transcriptional mechanisms (Gelsthorpe et al.,
2008). In addition, the NPC1 I1061T protein demonstrated an enhanced electrophoretic mobility, suggesting a less mature glycosylation state. Most of the NPC1 I1061T protein migrates as a ⬃140 kDa
band, which is the predicted weight of unmodified NPC1, whereas a
small proportion of presumably glycosylated NPC1 I1061T protein
appears as higher-molecular-weight bands. To determine
whether murine NPC1 I1061T protein has decreased stability, we
isolated hepatocytes from WT and Npc1I1061T littermates, treated
these primary cells with CHX to block new protein synthesis, and
quantified levels of NPC1 protein by Western blotting. Whereas
63% of WT NPC1 protein was remaining after treatment, only
33% of NPC1 I1061T protein remained after CHX treatment (Fig.
6D). These findings phenocopied the reduced stability of the mutant NPC1 protein in human skin fibroblasts derived from a patient homozygous for the NPC1I1061T mutation. The kinetics of
the NPC 1I1061T protein degradation in the murine hepatocytes
differed slightly from that in human fibroblasts, possibly reflecting cell- or species-specific differences (Fig. 6E). Moreover, digestion of liver and brain homogenate with endoglycosidase H,
which removes immature N-linked glycan residues, revealed that
a majority of murine NPC1 I1061T protein lacks mature glycosylation, indicating that it has been retained in the ER because of
misfolding (Fig. 6F ). We also found that the digested NPC1 I1061T
protein from brain homogenate migrates as a higher-molecularweight band compared with liver homogenate, indicating that
NPC1 I1061T protein may acquire additional post-translational
modifications in this organ. It has also been previously shown
that the buffers used in the digest reaction alter the apparent
mobility of NPC1 bands (Gelsthorpe et al., 2008), which explains
the difference in the appearance between Fig. 6, A and F.
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Figure 9. Lipidomic analysis of Npc1I1061T tissues. Lipid and sterol species were quantified from liver (A, B) and brain (C, D) homogenate via LC-MS/MS, and heat maps were generated as
described in Materials and Methods. Each tile represents a single animal (n ⫽ 4 per group). Z scores are represented in a gradient color scale; green represents the lowest value (⫺3), black represents
“0” value, and red represents the highest value (⫹3).
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Table 1. Lipidomic analysis of Npc1I1061T tissues

Npc1I1061T vs WT Liver

CER 16:0
CER 20:0
CER 22:0
CER 24:0
LC 16:0
LC 18:0
LC 20:0
LC 22:0
LC 24:0
LC 24:1
MC 16:0
MC 18:0
MC 22:0
MC 24:0
MC 24:1
SM 16:0
SM 18:0
SM 20:0
SM 22:0
SM 24:0
SM 18:1
SPH
S'PH
ST 20:0
GM2 16:0
GM2 18:0
GM2 22:0
GM3 16:0
GM3 22:0
FC
24 HC
Triol
7 Keto
27 HC
4 BETA
CE 16:0
CE 18:0
CE 18:1
CE 18:2
CE 20:4

P14
1.58
1.60
1.65
1.38
15.86
11.93
5.24
4.40
4.55
6.83
7.38
6.55
4.68
5.52
5.52
2.77
6.55
0.98
1.01
3.39
4.68
1.00
4.05
1.13
16.12
13.99
4.84
6.16
1.32
4.35
2.46
1.44
0.87
1.00
1.35
0.42
0.42
0.47
0.56
0.89

P28
1.76
1.64
1.04
1.02
17.02
29.23
10.00
8.63
9.79
11.75
5.10
5.39
2.56
3.38
3.93
2.33
6.03
0.74
0.55
2.07
5.35
5.94
6.50
0.77
95.15
17.19
5.23
2.89
0.94
4.33
2.49
1.35
0.77
0.57
2.06
0.99
1.15
0.85
1.20
1.01

P63
1.27
1.32
1.30
1.14
13.01
14.23
9.39
10.11
6.68
14.20
5.87
2.85
2.08
2.30
4.05
2.14
3.79
0.78
0.65
3.23
4.05
6.32
7.06
0.65
30.20
4.68
3.31
2.03
0.81
5.02
1.43
1.15
0.56
0.60
2.02
1.11
1.41
1.40
1.38
1.13

P105
2.09
1.48
0.99
1.00
14.47
19.86
16.42
17.73
10.73
20.24
4.91
3.57
2.57
3.18
4.27
2.42
4.61
0.65
0.58
2.41
4.24
11.52
14.20
0.98
38.11
8.96
5.69
1.42
0.84
4.30
2.36
2.09
1.11
0.52
4.83
2.44
2.31
2.12
2.08
0.98

Npc1I1061T vs WT Brain

CER 16:0
CER 20:0
CER 22:0
CER 24:0
LC 16:0
LC 18:0
LC 20:0
LC 22:0
MC 16:0
MC 18:0
MC 20:0
MC 22:0
MC 24:0
SM 16:0
0
SM 24:0
SM 18:1
SPH
S'PH
S1P
ST 20:0
GM2 18:0
GM3 18:0
FC
24 HC
Triol
7 Keto
27 HC
CE 16:0
CE 18:0
CE 18:1
CE 18:2
CE 20:4

P14
1.15
1.06
1.04
1.00
1.78
4.75
0.98
1.47
0.98
0.90
0.74
0.69
0.64
0.85
0.86
1.04
0.86
0.55
0.84
1.75
1.39
1.75
1.16
18.57
1.65
0.97
0.98
1.10
0.99
0.87
0.89
0.82
0.77
0.89
0.95

P28
1.05
1.24
1.39
1.54
1.85
5.04
0.95
1.35
1.18
1.58
1.10
1.09
1.10
1.12
0.95
1.02
1.04
0.76
0.92
1.55
1.36
1.55
0.91
11.70
3.41
0.97
0.98
1.26
1.05
0.52
2.42
1.60
1.51
1.94
1.63

P63
0.84
1.02
1.65
1.38
1.80
3.75
0.91
1.11
2.04
2.01
1.23
1.45
1.47
1.23
0.89
1.10
1.05
0.87
0.88
1.61
1.68
1.61
0.58
14.32
2.42
0.94
0.94
1.43
1.14
0.61
1.15
1.04
1.08
1.19
1.11

P105
0.72
1.11
1.55
1.16
1.99
4.34
0.70
0.84
1.79
1.69
1.51
1.31
1.41
1.52
1.04
1.01
1.10
0.71
0.89
1.82
1.70
1.82
0.63
8.63
2.87
1.08
0.96
1.25
0.57
0.58
5.43
2.75
3.16
1.32
1.25

p≤0.05
p≤0.01
p≤0.001

Fold change values of lipids quantified in liver and brain from Npc1I1061T mice compared with WT mice of the same age. n ⫽ 4 per group. Light gray, p ⱕ 0.05; dark gray, p ⱕ 0.01; black, p ⱕ 0.001; white, nonsignificant.

To determine whether the subcellular localization of
NPC1 I1061T protein is altered, we performed immunofluorescence staining in MEFs. In WT MEFs, NPC1 protein colocalized
with a LAMP1-positive, filipin-negative endolysosomal compartment. In contrast, in Npc1I1061T MEFs, the mutant protein
was expressed at much lower levels than WT NPC1 protein and
displayed a reticular staining pattern that was distinct from filipinpositive lysosomes and most consistent with ER localization (Fig. 7).
Together, these data indicate that murine NPC1 I1061T protein, like
the human mutant protein, is misfolded and targeted for ERassociated degradation, preventing its proper targeting to
endolysosomes.
Cytokine activation and inflammation in tissues in
Npc1 I1061T mice
A prominent feature of NPC1 disease models is profound inflammatory changes, particularly in brain tissue (Langmade et al., 2006).
We quantified inflammatory gene expression by performing RTqPCR on mRNA isolated from brain and liver tissue from Npc1I1061T
mice and WT littermates at P28, P63, and P105 (Fig. 8). Npc1I1061T
cerebellum tissue showed increased apolipoprotein E (apoE) and
GFAP expression compared with WT that was significant at P63 and
P105 (for P63 and P105, p ⬍ 0.05), consistent with glial activation
known to occur in response to neuronal cell death in NPC1 disease

(Fig. 8A; Baudry et al., 2003). This was accompanied by a dramatic
increase in expression of cytokines (TNF␣ and MIP1␣) and markers
of microglial activation (CD68 and CD11c), particularly late in disease progression (Figs. 3D, 5C, 8B). A similar pattern of induction of
inflammatory gene expression was present in liver tissue (Fig. 8C).
With the exception of apoE expression, no significant changes in
cholesterol homeostatic gene expression were observed in either
brain (Fig. 8A) or liver (data not shown) tissue.
Lipid accumulation in tissues of Npc1 I1061T mice
Previous studies have shown that multiple cholesterol-derived
metabolites and sphingolipid species accumulate in liver and
brain of the Npc1 ⫺/⫺ mouse model, and abundance of many
species increases with disease progression (Pentchev et al., 1980;
Goldin et al., 1992; Porter et al., 2010; Fan et al., 2013). To determine whether the I1061T missense mutation led to a similar lipid
storage phenotype, we broadly surveyed cholesterol-derived metabolites and sphingolipid de novo and recycling pathways in liver
and brain tissue from the Npc1I1061T, Npc1⫹/I1061T, and WT littermates (P14, P28, P63, and P105) and from Npc1 ⫺/⫺ mice and
WT littermates (P49). Lipid classes quantified by tandem mass
spectrometry included sphingoid bases, ceramides, sphingomyelins, monohexosylceramides and dihexosylceramides, gangliosides, sulfatides, unesterified and esterified cholesterol, and
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Figure 10. Lipidomic analysis of Npc1 ⫺/⫺ C57BL/6 and Balb/C strains. A, Lipid and sterol species were quantified in liver and brain homogenate from P49 Npc1 ⫺/⫺ C57BL/6 and Balb/C mice
via LC-MS/MS, and heat maps were generated as described in Materials and Methods. Values were normalized to WT C57BL/6. Each tile represents a single animal (n ⫽ 3–5 per group). Z scores are
represented in a gradient color scale; green represents the lowest value (⫺3), black represents “0” value, and red represents the highest value (⫹3). B, Fold change values of lipids quantified in A,
normalized to WT C57BL/6 mice. Significance was calculated via Student’s t test, comparing Npc1 ⫺/⫺ mice with their strain WT littermates. Blue, p ⬍ 0.05; green, p ⬍ 0.01; purple, p ⬍ 0.001;
white, nonsignificant.

oxysterols. The metabolomic profiles of brain and liver tissues from
Npc1⫹/I1061T and WT littermates were very similar, consistent with
previous profiling of heterozygotes in the Npc1 ⫺/⫺ mouse strain
(Fig. 9; Fan et al., 2013). The only significant differences were increased cholesteryl ester (16:0, 18:0, and 18:1) species in brain tissue
in P14 and P28 Npc1⫹/I1061T mice (Fig. 9C,D). In contrast,
metabolomic profiling revealed marked differences between
Npc1I1061T mice and age-matched WT littermates (Fig. 9, Table
1). A broad range of lipids accumulated in the liver tissue of P14
Npc1I1061T mice: lactosylceramides (16:0 and 18:0), monohexosylceramides (16:0, 20:0, 22:0, 24:0, and 24:1), sphingomyelins
(16:0, 18:0, and 24:0), sphingoid bases (sphinganine and sphingosine), gangliosides (GM2 16:0 and 18:0; GM3 16:0), unesterified cholesterol, and 24( S)-hydroxycholesterol (Fig. 9B). The
profound lipid storage in the suckling P14 mice likely reflects the
high lipid content of the mouse milk (Silverman et al., 1992)
since the lipid storage partially resolved after the mice were
weaned at P21. In the liver tissue of older Npc1I1061T mice,
there was age-dependent accumulation of multiple sphingolipid species. Significant increases were found among cer-

amide (24:0), monohexosylceramides (16:0, 20:0, 22:0, 24:0, and
24:1), lactosylceramides (20:0 and 22:0), sphingomyelins (18:1
and 24:0), sphingosine, and gangliosides (GM2 16:0, GM2 22:0,
and GM3 16:0; Fig. 9A). The sphingolipid accumulation was accompanied by significant increases in unesterified cholesterol,
24( S)-hydroxycholesterol, and 3␤,5␣,6␤-cholestan-triol (Table
1, Fig. 9A). Sphingolipids were also elevated in the brain tissue of
the Npc1I1061T mice, with significant increases found in lactosylceramide (20:0), sulfatide (20:0), sphinganine, and GM3 ganglioside (GM3 18:0) species (Fig. 9C). No significant differences in
cholesterol or oxysterol species were detected in bulk brain tissue.
Although the sphingolipid and cholesterol storage phenotype
in the Npc1I1061T mice was consistent with findings previously
reported in the Npc1 ⫺/⫺ mice (Hùlková et al., 2005; Fan et al.,
2013), we were intrigued by the observation that Npc1I1061T mice
principally accumulate monohexosylceramides and lactosylceramides in brain and liver tissues, whereas Npc1 ⫺/⫺ mice store
relatively more gangliosides (GM2 and GM3; Table 1, Fig. 9). To
assess whether the distinct lipid storage patterns reflected the
difference between a partially functional NPC1 missense muta-
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Figure 11. Effect of SAHA treatment on lysosomal cholesterol in Npc1I1061T MEFs. Cells were treated with 10 M SAHA or DMSO
(vehicle control) for 72 h. A, Fluorescence images of cells treated with SAHA or DMSO vehicle and stained with filipin. B, Quantification of lysosomal filipin staining, normalized to Npc1I1061T DMSO. Values represent the average of three experiments. C, Western
blot analysis of MEFs treated with SAHA, with quantification (bottom). The blots are representative of three experiments. *p ⬍
0.05; ***p ⬍ 0.001.

tion and a null mutation or differences in genetic background
(Npc1I1061T and Npc1 ⫺/⫺ mice are hosted in the C57BL/6 and
BALB/c strains, respectively), we obtained brain and liver tissues
from Npc1 ⫺/⫺ mice backcrossed into the C57BL/6 background.
Metabolomic profiling was performed in P49 Npc1 ⫺/⫺ mice in
both genetic backgrounds and demonstrated that although there
are only minor differences between the BALB/c and C57BL/6 WT
lipid profiles, livers from C57BL/6 Npc1 ⫺/⫺ mice accumulate
more ceramides (16:0, 18:0, 20:0, and 24:1), monohexosylceramides (22:0 and 24:0), sphingomyelins (16:0, 18:0, 20:0, and
24:0), sphingoid bases (SPH, S’PH, and 3-keto S’PH), gangliosides (GM2 16:0, 18:0, and 22:0; GM3 16:0 and 22:0), free cholesterol, 24( S)-hydroxycholesterol, 4␤-hydroxycholesterol, and
cholesterol ester (18:1) compared with their BALB/c Npc1 ⫺/⫺
counterparts (Fig. 10). Fewer differences were seen in brain tissue, where C57BL/6 Npc1 ⫺/⫺ mice accumulate more ceramide
(24:1), lactosylceramide (24:1), and 3␤,5␣,6␤-cholestan-triol
(Fig. 10).
Treatment with HDAC inhibitors corrects the cholesterol
storage phenotype in Npc1 I1061T MEFs
In recent studies, we showed that treatment of human NPC1
mutant cells with certain HDAC inhibitors, including the nonselective HDAC inhibitor SAHA, leads to clearance of excess cholesterol and other lipids from late endosomes/lysosomes and

corrects the overall defect in cholesterol
regulation (Pipalia et al., 2011). These
changes were accompanied by increased
expression of NPC1 I1061T mutant protein.
To determine whether the murine
NPC1 I1061T protein in the knock-in mice
responded in a similar manner as human
NPC1 I1061T fibroblasts to a proteostatic
therapy, we isolated MEFs from day 13.5
Npc1I1061T and WT littermate embryos
and treated them with SAHA, and filipin
labeling of late endosomes/lysosomes
was quantified as described previously
(Pipalia et al., 2011). Compared with
DMSO vehicle controls, SAHA-treated
Npc1I1061T MEFs had reduced free cholesterol storage, as determined by filipin
staining (Fig. 11 A, B). A similar effect was
observed in WT cells in which we have
previously shown that half of newly synthesized NPC1 is normally degraded
(Gelsthorpe et al., 2008). We found that
the decrease in lysosomal-free cholesterol
in SAHA-treated Npc1I1061T MEFs was attributable to an increase in the abundance
of NPC1 I1061T protein, as shown by Western blot analysis (Fig. 11C). We also observed that SAHA treatment increases
the amount of high-molecular-weight
NPC1 I1061T protein, which likely corresponds to glycosylated, mature protein
that is appropriately localized to the lysosome. A trend toward increased NPC1
protein was likewise observed in the
SAHA-treated WT MEFs.

Discussion

Herein, we generated and characterized a
novel NPC1 disease model, the Npc1I1061T
knock-in mouse. Introduction of the I1061T missense mutation
into the murine NPC1 locus destabilized the NPC1 protein and
prevented targeting to late endosomes/lysosomes, mimicking the
effects of this mutation in human fibroblasts. Phenotypically, the
reduced lifespan, altered growth curves, and progressive decline
in motor coordination were all consistent with NPC1 disease,
though milder than the severe infantile form of the disease modeled by the BALB/c Npc1 ⫺/⫺ mouse. Similar to the Npc1⫺/⫺
mice, we identified a progressive and complex neuropathology,
including stereotypic Purkinje cell loss in the cerebella of
Npc1I1061T mice, which was antecedent to motor dysfunction
and is a neuropathological hallmark of the disease (Higashi et
al., 1993; Vanier, 2010). The neurological phenotype was accompanied by astrogliosis, inflammatory gene expression, and storage of cholesterol-derived and sphingolipid species in liver and brain
tissues, mirroring the changes reported in human NPC1 disease
(Vanier, 1983, 1999; Walkley and Suzuki, 2004; Cologna et al., 2014).
In summary, this novel mouse model faithfully recapitulates disease
caused by the human NPC1 I1061T mutation and provides a powerful
tool for preclinical evaluation of proteostatic therapies for NPC1
disease. Moreover, the Npc1I1061T knock-in mouse may have
broader use as a more general model for the study of protein misfolding in vivo.
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Compared with the BALB/c Npc1 ⫺/⫺ mouse, the phenotype
of the Npc1I1061T model is delayed because of the expression of the
partially functional NPC1 I1061T protein. Whereas WT and
Npc1 I1061T mice express similar levels of NPC1 mRNA, NPC1
protein levels are sharply reduced in liver and brain tissues from
Npc1I1061T mice. The reduced half-life of the murine NPC1 I1061T
protein and the endoglycosidase H sensitivity pattern, indicating
failure of the mutant protein to process to a post-ER compartment,
is consistent with our previous finding of reduced NPC1 protein
stability in NPC1 I1061T human skin fibroblasts and demonstrates
that a majority of NPC1 I1061T protein is misfolded and targeted
for degradation (Gelsthorpe et al., 2008). The immunofluorescence staining pattern for the NPC1 I1061T protein, which revealed
that the majority of the mutant protein failed to colocalize with
LAMP1, a late endosomal/lysosomal marker, also supports a
model in which the mutant protein is retained within the ER.
Intriguingly, we found differences in the electrophoretic mobility
of WT and NPC1 I1061T proteins from liver and brain tissues.
Endoglycosidase H and PNGase F digestion of WT protein from
these tissues suggests that the NPC1 protein may be differentially
glycosylated in the liver and brain. The NPC1 I1061T protein is
sensitive to both glycosidases in both tissues, suggesting that its
impaired folding prevents trafficking through the ER and the
addition of N-linked sugar residues. The higher molecular weight
of NPC1 I1061T in brain tissue also suggests this protein may be
subject to other post-translational modifications. At present, the
relevance of such tissue-specific differences in protein modification to normal physiology or disease pathophysiology is uncertain.
CNS lipid storage is central to the pathophysiology of NPC
disease and precedes the inflammation and microglial activation
that accompany neuronal loss (Reid et al., 2004). Neuropathological assessment and metabolomic analysis of brains from
Npc1I1061T knock-in mice revealed age-dependent accumulation
of a broad range of sphingolipid classes, notably sphingoid bases,
monohexosylceramides and dihexosylceramides, sphingomyelins, and gangliosides. This pattern of storage is similar to the
brain tissue profile previously reported for Npc1 ⫺/⫺ mice (Fan et
al., 2013), demonstrating that the knock-in mouse faithfully
models NPC1 disease. Although the general consensus is that the
primary defect in NPC1 disease is impaired endolysosomal cholesterol export, the cholesterol accumulation is invariably accompanied by secondary storage of sphingolipids (Pentchev et al.,
1980, 1984; Vanier, 1983, 1999; Goldin et al., 1992), perhaps
caused by the well established biophysical association of cholesterol and sphingolipids in membrane bilayers. The finding that
miglustat, a partial inhibitor of glucosylceramide synthase, provides disease amelioration in NPC1 animal models and the fact
that limiting synthesis of complex gangliosides leads to reduced
cholesterol accumulation imply a critical role for sphingolipid
storage in disease pathogenesis (Zervas et al., 2001; Gondré-Lewis
et al., 2003; Zhou et al., 2011; Stein et al., 2012; Lee et al., 2014). In
contrast to the sphingolipid species, unesterified cholesterol levels in bulk brain tissue are not elevated. Rather, cholesterol storage is evident only by cytochemical analysis of brain tissue
sections, predominantly in nuclei containing large neurons that
have high obligate rates of cholesterol flux (Dietschy and Turley,
2004).
The Npc1I1061T mice similarly exhibit profound lipid storage
in peripheral tissues that is a prominent feature in NPC1 animal
models and human NPC1 disease (Pentchev et al., 1980; Vanier,
1983; Zervas et al., 2001; Maue et al., 2012; Fan et al., 2013). As in
the brain tissue, sphingolipid storage in liver tissue steadily in-
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creases from P28 to P105, which correlates with disease progression, but, in contrast to brain tissue, is accompanied by increased
unesterified cholesterol in bulk tissue. Along with increased cholesterol stores, there is an attendant elevation of 3␤,5␣,6␤cholestan-triol, a nonenzymatic oxidation product that is an
NPC1-specific biomarker of disease (Porter et al., 2010; Jiang et
al., 2011), which reflects the unique intersection of elevated unesterified cholesterol and oxidative stress in NPC disease (Zampieri et al., 2009; Zhang et al., 2008; Smith et al., 2009).
An unexpected finding was the massive lipid storage in the
suckling P14 knock-in mice. The elevation was transient, as cholesterol and sphingolipid content were reduced after weaning
(e.g., in P28 mice), strongly implicating the high lipid content of
the mouse milk (Silverman et al., 1992). Moreover, the lipid storage in the suckling mice was observed in liver but not in brain
tissue, further supporting an exogenous origin for the lipid, since
dietary cholesterol does not cross the blood– brain barrier (Dietschy and Turley, 2004). The lipid storage phenotype in liver tissue
in the neonatal knock-in mice closely mirrors the profound cholesterol storage in human NPC1 neonates, approximately half of
whom present with prolonged jaundice or hepatosplenomegaly
(Vanier, 2010).
The genetic background of Npc1I1061T mice appears to have
profound modulatory effects on the NPC1 disease phenotype.
Initially, the knock-in mice were backcrossed in the BALB/c
strain to permit comparison with the Npc1 ⫺/⫺ mice in the same
background. Although the NPC1 disease phenotype (e.g., tremor
and reduced lifespan) was readily apparent in the mice in the
mixed 129/BL6 background, this phenotype was markedly attenuated once backcrossed into the BALB/c background (our unpublished observations A. Lieberman and D. Ory). In this genetic
background, there was no overt neurological phenotype in
6-month-old mice, and disease was only detectable neuropathologically (data not shown), prompting us to re-establish the
knock-in mice in the more permissive C57BL/6 background.
Consistent with this finding, metabolomic profiling of the
Npc1 ⫺/⫺ mice revealed significant differences in the extent of
cholesterol and sphingolipid storage between the different genetic backgrounds. Compared with Npc1 ⫺/⫺ mice in the BALB/c
background, Npc1 ⫺/⫺ mice in the C57BL/6 background displayed an increased accumulation of ceramide species, sphingomyelins, sphingoid bases, gangliosides, free cholesterol, and
oxysterols in peripheral tissues. We hypothesize that the BALB/c
strain harbors a modifier gene that confers protection against
NPC disease (Collins et al., 2006). This putative modifier gene
could help stabilize the NPC1 I1061T protein in the ER by modulating endogenous chaperones (Yang et al., 2013), allowing more
time for the NPC1 I1061T protein to achieve proper conformation
for entry into the post-ER secretory pathway, and ultimately be
targeted to endolysosomes. Alternatively, the modifier gene
might act to decrease subcellular lipid accumulation, either by
regulating synthesis/processing of sphingolipids or by facilitating
endolysosomal cholesterol release through NPC1-independent
trafficking pathways (Abi-Mosleh et al., 2009; Cianciola et al.,
2013). This variable penetrance of the NPC1 phenotype in the
different genetic backgrounds will provide an opportunity in future studies to identify modifier genes that contribute to
NPC1 I1061T protein stabilization.
The Npc1I1061T knock-in mouse presents a unique tool to assess candidate proteostatic therapies in vivo. Whereas the
Npc1 ⫺/⫺ mouse model continues to be a valuable reagent in
understanding and treating NPC disease, it is not amenable to
testing therapies aimed at modulation of expression and/or post-
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translational protein processing. Our novel Npc1I1061T mouse
model not only overcomes this limitation, but also harbors the
most common disease-causing mutation in human NPC1 disease. We show that in MEFs derived from the knock-in mice,
SAHA treatment rescues the cholesterol trafficking phenotype,
similar to results reported in human NPC1 I1061T fibroblasts (Kim
et al., 2007; Munkacsi et al., 2011; Pipalia et al., 2011). Together
with the biochemical and immunofluorescence analysis of the
NPC1 I1061T protein in the mouse tissues, these data indicate that
the cellular behavior of the mutant protein closely models that of
the most common disease-causing mutation in the human NPC1
locus (Gelsthorpe et al., 2008) and provide proof of concept that
the mouse model will respond similarly to interventions that
stabilize the human NPC1 I1061T protein. Moreover, as the NPC1
mutation spectrum is dominated by single amino acid substitutions, this model may also provide general insights into pathogenic mechanisms evolving from impaired NPC1 protein
stability caused by mutations other than I1061T.
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